Xponance Inc. Sells 1,563 Shares of UiPath Inc. (NYSE:PATH)

Xponance Inc. lowered its stake in shares of UiPath Inc. (NYSE:PATH) by 3.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,283 shares of the healthcare company’s stock after selling 1,563 shares during the quarter. Xponance Inc.’s holdings in UiPath were worth $1,075,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in PATH. CWM LLC boosted its position in UiPath by 19.6% during the third quarter. CWM LLC now owns 8,799 shares of the healthcare company’s stock worth $151,000 after purchasing an additional 1,439 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in shares of UiPath by 104.4% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 102,000 shares of the healthcare company’s stock worth $1,745,000 after buying an additional 52,100 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in shares of UiPath by 196.8% during the third quarter. Robeco Institutional Asset Management B.V. now owns 332,715 shares of the healthcare company’s stock worth $5,693,000 after buying an additional 220,618 shares during the last quarter. Raymond James & Associates lifted its holdings in shares of UiPath by 51.0% during the third quarter. Raymond James & Associates now owns 89,534 shares of the healthcare company’s stock worth $1,532,000 after buying an additional 30,244 shares during the last quarter. Finally, Bangor Savings Bank lifted its holdings in shares of UiPath by 4.0% during the third quarter. Bangor Savings Bank now owns 62,893 shares of the healthcare company’s stock worth $1,076,000 after buying an additional 2,406 shares during the last quarter. Institutional investors own 62.50% of the company’s stock.

Analysts Set New Price Targets

PATH has been the subject of a number of research analyst reports. TD Cowen upped their price target on UiPath from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, March 14th. BMO Capital Markets upped their price target on UiPath from $24.00 to $28.00 and gave the stock a “market perform” rating in a report on Thursday, March 14th. Morgan Stanley upped their target price on UiPath from $17.00 to $25.00 and gave the company an “equal weight” rating in a research note on Thursday, March 14th. Needham & Company LLC restated a “buy” rating and issued a $30.00 target price on shares of UiPath in a research note on Wednesday, March 20th. Finally, Evercore ISI upped their target price on UiPath from $24.00 to $27.00 and gave the company an “in-line” rating in a research note on Thursday, March 14th. Nine equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $27.41.

Insider Transactions at UiPath

In other news, CFO Ashim Gupta sold 16,000 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $22.47, for a total transaction of $359,520.00. Following the sale, the chief financial officer now owns 103,505 shares in the company, valued at $2,325,757.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 72,000 shares of company stock worth $1,591,360. Insiders own 31.03% of the company’s stock.

UiPath Stock Performance

Shares of PATH stock opened at $19.69 on Thursday. The stock’s fifty day moving average is $22.42 and its 200-day moving average is $21.55. UiPath Inc. has a 52 week low of $12.38 and a 52 week high of $27.87.

UiPath (NYSE:PATH) last announced its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.10. The company had revenue of $405.25 million for the quarter, compared to analysts’ expectations of $383.32 million. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. As a group, analysts predict that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.